目的:观察血必净注射液联合铂类方案治疗晚期癌症患者的疗效和毒性反应。方法:将91例晚期癌症患者随机分为联合组(46例,接受血必净注射液联合化疗)和对照组(45例,仅接受化疗)。两组的化疗均为含铂类联合方案。比较两组的近期疗效和急性毒副反应的差异。结果:两组的有效率差异无统计学意义(P>0.05)。联合组的恶心、呕吐和腹泻的发生率分别为63.0%、41.3%和8.9%,分别明显低于对照组的86.7%、64.4%和24.4%(均P<0.05),疲乏和肾功能损害的发生率亦明显低于对照组(均P<0.05)。两组的肝功能损害和骨髓毒性反应差异无统计学意义。联合组的KPS评分明显优于对照组(P<0.05)。结论:中药制剂血必净注射液能明显降低肿瘤患者含铂类方案化疗的相关毒性反应,改善患者的生活质量。 Objective: To observe the efficacy and toxicity of Xuebijing injection combined with platinum regimen in the treatment of advanced cancer patients. Methods: Ninety-one patients with advanced cancer were randomly divided into combined group (46 patients receiving Xuebijing injection combined with chemotherapy) and control group (45 patients receiving chemotherapy only). The two groups of chemotherapy are platinum-containing joint program. The short-term efficacy and acute side effects of the two groups were compared. Results: There was no significant difference in the effective rates between the two groups (P> 0.05). The incidence of nausea, vomiting and diarrhea in the combination group were 63.0%, 41.3% and 8.9%, respectively, which were significantly lower than those in the control group (86.7%, 64.4% and 24.4%, respectively; P <0.05) The incidence was also significantly lower than that of the control group (all P <0.05). Two groups of liver dysfunction and bone marrow toxicity differences were not statistically significant. The KPS score of the combined group was significantly better than that of the control group (P <0.05). Conclusion: The Chinese traditional medicine preparation Xuebijing injection can obviously reduce the toxic reaction of platinum-containing chemotherapy in cancer patients and improve the quality of life of patients.